Could Glucagon be a Therapeutic Option in the Management of Acute Aluminium Phosphide Toxicity?
Mohammad Arefi* and Narges Tabrizchi
Tehran University of Medical Sciences, Baharloo Hospital, Iran
- corresponding Author:
- Mohammad Arefi
Tehran University of Medical Sciences
Baharloo Hospital, Iran
E-mail: mare[email protected]
Received Date: October 12, 2012; Accepted Date: November 02, 2012; Published Date: November 27, 2012
Citation: Arefi M, Tabrizchi N (2012) Could Glucagon be a Therapeutic Option in the Management of Acute Aluminium Phosphide Toxicity? Endocrinol Metab Synd 2:109. doi: 10.4172/2161-1017.1000109
Copyright: © 2012 Arefi M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Acute aluminum phosphide is a severe toxicity in Iran and the other countries such as India. Morbidity and mortality of this toxicity are high because of the absence of any antidote. Its mortality is related to releasing of phosphine gas after ingesting of this poison. Objective: Cardiovascular collapse and hypotension are the main factors which result in death in this toxicity. Although serum therapy is essential in its management, the vasopressors play an important role too. Discussion: Glucagon is a pancreatic polypeptide hormone that has diverse utility as both a therapeutic and diagnostic agent. It has been used as an effective therapeutic agent for beta blocker and calcium channel blocker toxicity and shock for many years. Summary: We propose that glucagon can dominate the refractory hypotension and myocardial depression in combination with serum therapy and vasopressors in aluminum phosphide toxicity.